GSA Capital Partners LLP Invests $126,000 in HilleVax, Inc. (NASDAQ:HLVX)

GSA Capital Partners LLP purchased a new position in HilleVax, Inc. (NASDAQ:HLVX) in the 3rd quarter, HoldingsChannel reports. The firm purchased 71,463 shares of the company’s stock, valued at approximately $126,000.

Other large investors also recently added to or reduced their stakes in the company. Tidal Investments LLC bought a new stake in shares of HilleVax in the 1st quarter valued at approximately $207,000. Maven Securities LTD purchased a new stake in HilleVax during the 2nd quarter valued at $217,000. Algert Global LLC purchased a new stake in HilleVax during the 2nd quarter valued at $519,000. Rhumbline Advisers lifted its position in HilleVax by 27.0% in the second quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock worth $617,000 after buying an additional 9,073 shares during the last quarter. Finally, TD Asset Management Inc raised its stake in shares of HilleVax by 53.9% in the second quarter. TD Asset Management Inc now owns 54,236 shares of the company’s stock valued at $784,000 after acquiring an additional 19,000 shares during the period. 86.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price target on shares of HilleVax in a research note on Monday, August 12th. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, HilleVax currently has an average rating of “Hold” and an average target price of $3.00.

HilleVax Stock Up 4.3 %

HLVX stock opened at $1.94 on Tuesday. HilleVax, Inc. has a twelve month low of $1.55 and a twelve month high of $20.22. The firm has a market cap of $96.63 million, a price-to-earnings ratio of -0.63 and a beta of 0.78. The business’s fifty day simple moving average is $1.83 and its two-hundred day simple moving average is $5.26.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). Research analysts expect that HilleVax, Inc. will post -2.64 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.